Lignium combats greenhouse gasses with a green fuel that boasts an enviably low carbon footprint. Photo courtesy of Lignium

In Houston, air pollution is usually more of an abstract concept than a harsh reality. But in parts of Chile, the consequences of heating homes with wet wood are catching up to residents.

“Given all the contamination, there are times kids aren’t allowed to go to school. The air pollution is really affecting people’s health,” says Agustín Ríos, COO of Lignium Energy.

Additionally, the methane and nitrous oxide produced by cattle farming are a problem. But Lignium Energy, an international company started in Chile and now headquartered in Houston’s Greentown Labs, has a solution that can solve both problems by upending the latter.

“There’s a lack of solutions with the problem of manure. Methane gases are destroying our planet,” says CEO and co-founder Enrique Guzmán. He goes on to say that most solutions currently being developed are expensive and complex. But not Lignium Energy’s method, invented by co-founder José Antonio Caraball.

Caraball has patented an extraordinarily simple concept. Lignium separates the solid from liquid excretions, then cleans the solid to generate a hay-like biomass. Biomass refers to organic matter that can be used as fuel. What Lignium makes from the cattle evacuations is a clean, odorless and highly calorific biomass.

Essentially, Lignium combats greenhouse gasses with a green fuel that boasts an enviably low carbon footprint. “Our process is very cheap and very simple. That’s why we are a great solution,” explains Guzmán.

Caraball, an industrial engineer, came up with the idea six years ago, says Guzmán. Five years ago, he began working with the company, one year ago, Guzmán and Ríos picked up and moved to Houston.

“We decided to move out of Chile due to market size,” says Ríos. However, the product is already being sold to consumers in its homeland.

Why Houston? The reason was twofold. As an energy company, Ríos says that they wanted to be in “the energy capital of the world.” But Texas is also one of the largest sites of cattle farming on the planet. Lignium prefers to work with farms with more than 500 head to optimize harvesting the waste that becomes biomass.

With that in mind, Lignium has partnered with Southwest Regional Dairy Center in Stephenville, Texas, a little more than an hour southwest of Fort Worth, a town known as the world’s rodeo capital. The facility is associated with Texas A&M, though Guzmán says Lignium is not officially associated with the university.

Guzmán says that the company is currently hiring a team member to help Lignium figure out commercial logistics, as well as four or five other Houstonians who will help them take their product to market in the United States, and eventually around the globe. For now, he predicts that they will be able to sell to consumers in this country by early next year, if not the fourth quarter of 2023.

“We are very committed to the solution because, at the end of the day, if we do good work with the company, we are sure we can give better conditions to the cattle industry,” says Guzmán. “Then we can make a big impact on a real problem.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”